Novartis (NVS) PT Raised to $170 at Morgan Stanley

March 26, 2026 3:21 AM

Morgan Stanley analyst Thibault Boutherin raised the price target on Novartis (NYSE: NVS) to $170.00 (from $143.00) while maintaining a Overweight rating.

No results found